ទំព័រដើម › មហារីកទ្រូង › មីសូរី › Kansas City
ការសាកល្បងគ្លីនិកសម្រាប់ មហារីកទ្រូង នៅក្នុង Kansas City, MO
ការសិក្សាចំនួន 34 សម្រាប់ មហារីកទ្រូង កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Kansas City (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
The Vanguard Study: Testing a New Way to Screen for Cancer
កំពុងជ្រើសរើសស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Saint Luke's Hospital of Kansas City, Kansas City
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- University of Kansas Cancer Center, Westwood · ឆ្ងាយ 5 ម៉ាយ
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- HCA Midwest Division, Kansas City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Kansas City Veterans Affairs Medical Center, Kansas City
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Saint Luke's Cancer Institute, Kansas City
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- St. Lukes Hospital of Kansas City, Kansas City
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Saint Luke's Cancer Institute ( Site 0027), Kansas City
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
កំពុងជ្រើសរើសដំណាក់កាល 3
- The University of Kansas Cancer Center, Westwood · ឆ្ងាយ 5 ម៉ាយ
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Saint Luke's Cancer Institute ( Site 0059), Kansas City
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Clinical Trial Site, Kansas City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Saint Luke's Cancer Institute, Kansas City
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Saint Luke's Hospital of Kansas City, Kansas City
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Saint Luke's Hospital of Kansas City, Kansas City
A Phase 1/1b Study of IAM1363 in HER2 Cancers
កំពុងជ្រើសរើសដំណាក់កាល 1
- Saint Luke's Cancer Institute, Kansas City
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- HCA Midwest Division, Kansas City
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- HCA Midwest Health, Kansas City
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
កំពុងជ្រើសរើសដំណាក់កាល 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- និង 1 ទៀត
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Universtiy Health, Kansas City
- KCCC South, Kansas City
- Research Medical Center, Kansas City
- និង 2 ទៀត
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
កំពុងជ្រើសរើសដំណាក់កាល 3
- University of Kansas Cancer Center - North, Kansas City
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Saint Luke's Cancer Institute, Kansas City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- University of Kansas Medical Center (KUMC), Westwood · ឆ្ងាយ 5 ម៉ាយ
HER2-positive Breast Cancer Registry
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- The University of Kansas Cancer Center, Westwood · ឆ្ងាយ 5 ម៉ាយ
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Saint Luke's Cancer Institute, Kansas City
Integrated Cancer Repository for Cancer Research
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- និង 1 ទៀត
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
កំពុងជ្រើសរើសដំណាក់កាល 3
- Saint Luke's Cancer Institute, Kansas City
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Saint Luke's Cancer Institute, Kansas City
- The University of Kansas Cancer Center, Westwood · ឆ្ងាយ 5 ម៉ាយ
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- The University of Kansas Cancer Center - North, Kansas City
- KUCC - Briarcliff, Westwood · ឆ្ងាយ 5 ម៉ាយ
- KUCC - Olathe, Westwood · ឆ្ងាយ 5 ម៉ាយ
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
កំពុងជ្រើសរើសដំណាក់កាល 3
- Saint Luke's Hospital of Kansas City, Kansas City
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
កំពុងជ្រើសរើសដំណាក់កាល 3
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · ឆ្ងាយ 2 ម៉ាយ
- និង 1 ទៀត
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- The University of Kansas Cancer Center, Westwood · ឆ្ងាយ 5 ម៉ាយ
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- និង 1 ទៀត
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Saint Luke's Hospital of Kansas City, Kansas City
- University of Kansas Cancer Center, Westwood · ឆ្ងាយ 5 ម៉ាយ
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
កំពុងជ្រើសរើសការសិក្សាសង្កេត
- Massive Bio SYNERGY-AI site, Kansas City
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
កំពុងជ្រើសរើសដំណាក់កាល 3
- Truman Medical Centers, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City · ឆ្ងាយ 2 ម៉ាយ
- និង 1 ទៀត
ការសាកល្បងសម្រាប់ មហារីកទ្រូង នៅក្នុងទីក្រុងផ្សេងទៀត
- New York City, NYការសិក្សា 136
- Houston, TXការសិក្សា 126
- Boston, MAការសិក្សា 112
- Nashville, TNការសិក្សា 81
- Los Angeles, CAការសិក្សា 73
- Edison, NJការសិក្សា 68
- St. Louis, MOការសិក្សា 64
- Queens, NYការសិក្សា 64
- Durham, NCការសិក្សា 64
- Chicago, ILការសិក្សា 59
- Philadelphia, PAការសិក្សា 56
- Dallas, TXការសិក្សា 55
ការសិក្សាផ្សេងទៀតនៅក្នុង Kansas City
- Non-Small Cell Lung Cancerការសិក្សា 31
- បេះដូងខ្សោយការសិក្សា 25
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 21
- មហារីកសួតការសិក្សា 19
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 16
- មហារីកដែលរីករាលដាលការសិក្សា 15
- ជំងឺលីកូសេមីមីអេឡូអ៊ីដបន្ទាន់ការសិក្សា 15
- មហារីកតូចការសិក្សា 14
- មហារីកស៊ុតការសិក្សា 11
- ជំងឺធាត់ការសិក្សា 11
- ជំងឺទឹកនោមផ្អែមប្រភេទ ២ការសិក្សា 11
- ជំងឺបេះដូង និងសរសៃឈាមការសិក្សា 11
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។